CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Medical Coverage Policy Saturation Biopsy for Diagnosis, Staging and Management of Prostate Cancer

Defines BCBSRI coverage position on saturation biopsy (>20 cores, transrectal or transperineal stereotactic template-guided) when used for diagnosis, staging, or management of prostate cancer for Commercial and Medicare Advantage products; includes related coding guidance.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMedical Coverage Policy Saturation Biopsy for Diagnosis, Staging and Management of Prostate Cancer

Policy CodePolicy N/A

Change TypeClarifiedAdded coding guidance

Effective DateOct 1, 2015

Next Review Date

Key ActionWhen performing saturation sampling claims should not be filed with codes 55700 or G0416; use 55706 (which is not covered for Medicare Advantage and not medically necessary for Commercial products).

SourceLink

POLICY UPDATE CHANGES

Policy states saturation biopsy is not covered / not medically necessary for diagnosis, staging, and management of prostate cancer.

Coding guidance specifying CPT 55706 and advising not to file 55700 or G0416 when performing saturation sampling.

1Primary coverage stance (Not medically necessary)

>20Saturation core count threshold

55706Key CPT called out

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Overview: This policy addresses saturation prostate biopsy (used for diagnosis, staging, or management of prostate cancer) and states the coverage position. Coverage stance: Not covered / Not medically necessary for the listed indications. Effective date: 2015-10-01; Last review: 2022-10-05. Threshold: saturation generally defined as more than 20 cores (>20 cores).

Policy facts

Effective Date2015-10-01

Last Review2022-10-05

Coverage StanceNot covered / Not medically necessary (for diagnosis, staging, and management of prostate cancer)

Saturation core count threshold> 20 cores

Key CPT called out55706 (Not covered for Medicare Advantage; not medically necessary for Commercial)

Medical-Necessity Criteria

Policy Statement - Coverage Determination

Saturation biopsy is considered not covered / not medically necessary when used for diagnosis, staging, or management of prostate cancer because evidence is insufficient to demonstrate improved net health outcomes.

Definition of saturation biopsy: Saturation biopsy (generally defined as >20 cores with improved sampling of anterior zones; may be transrectal or transperineal stereotactic template-guided)> 20 cores
Evidence on outcomes: Evidence is insufficient to determine that saturation biopsy results in improvement in net health outcomes (overall survival, disease-specific survival, progression, or clinically meaningful treatment outcomes); studies show higher detection rates but did not demonstrate improved progression or survival and may detect clinically insignificant cancers
Coverage conclusion:

Not Covered / Not Medically Necessary Details

Rationale: Evidence shows saturation biopsy yields higher cancer detection rates compared with extended protocols in some settings, but studies have not demonstrated improved health outcomes (overall survival, disease-specific survival, progression).

Supporting points:

- Systematic review and subsequent studies found higher detection rates with saturation versus extended biopsy but did not report patient-centered health outcomes (eg, survival) or demonstrate improved progression or survival.

- In the repeat-biopsy setting several studies showed increased detection, but about one-third of positive findings in at least one study were clinically insignificant, raising concern for overdiagnosis.

- Overall evidence is insufficient to conclude that increased detection with saturation translates into improved net health outcomes, and detection of clinically insignificant cancers could lead to unnecessary treatment and associated harms.

Coding Guidance

Not covered / not medically necessary CPTCPTNot Covered

55706

Biopsies, prostate, needle, transperineal, stereotactic template guided saturation sampling, including imaging guidance

Codes not to be filed when performing saturation samplingCPT|HCPCSNot Covered

55700	Biopsy, prostate; needle or punch, single or multiple, any approach
G0416	Prostate needle biopsy, percutaneous, any approach; including ultrasound guidance, when performed

Coding/Operational note: Use CPT 55706 for saturation transperineal stereotactic template-guided saturation sampling. When performing saturation sampling, do not file CPT 55700 or HCPCS G0416; 55706 is the designated saturation sampling code. Payer-specific guidance: 55706 is listed as not covered for Medicare Advantage and not medically necessary for Commercial products; verify member-specific benefits and Evidence of Coverage for applicable determinations.

Provider Actions & Billing Rules

Billing Rule

Do not file conflicting codes for saturation biopsy

When performing saturation sampling claims should not be filed with codes 55700 or G0416; use appropriate code for saturation (55706) which is not covered for Medicare Advantage and is not medically necessary for Commercial Products.

Affected codes: 55706, 55700, G0416
55706: not covered for Medicare Advantage and not medically necessary for Commercial products
Do not file 55700 or G0416 when performing saturation sampling

Documentation Required

Refer to member benefit documents

Benefits may vary between groups and contracts; providers must consult the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable coverage determinations.

Background, Evidence, & Definitions

What saturation biopsy entails: Saturation biopsy generally involves obtaining substantially more cores than standard extended protocols—commonly defined as more than 20 cores (>20)—to improve sampling of anterior zones that may be undersampled by routine approaches. Techniques may include transrectal or transperineal stereotactic template-guided approaches (the transperineal approach often performed with general anesthesia).

Clinical implications: Saturation sampling can increase cancer detection rates in some populations (initial or repeat biopsy settings) but has not been shown to improve clinically meaningful health outcomes; it may identify clinically insignificant cancers that could lead to overtreatment.

Study / Source	Key Findings
Systematic review (2013)	Found higher cancer detection rates with saturation vs extended overall, but small difference in men with PSA <10 ng/mL and no reported health outcomes.
Post-review studies	Several studies showed higher detection rates in repeat biopsy setting but did not demonstrate improved progression or survival; some positives were clinically insignificant.
BCBSRI Policy Statement	Saturation biopsy is not covered/not medically necessary for diagnosis, staging, and management of prostate cancer because evidence is insufficient to show improved net health outcomes.
Coding guidance (CPT)	CPT 55706 (transperineal stereotactic template-guided saturation sampling) is identified as not covered for Medicare Advantage and not medically necessary for Commercial Products; claims should not be filed with 55700 or G0416 when performing saturation sampling.

Definitions

TermSaturation biopsy

DefinitionGenerally considered as more than 20 cores taken from the prostate, with improved sampling of anterior zones; may be transrectal or transperineal (transperineal often template-guided with general anesthesia).

Revision History

2015-10-01policy_effective_date

Policy effective date 2015-10-01 (Medical Coverage Policy: Saturation Biopsy for Diagnosis, Staging and Management of Prostate Cancer).

2022-10-05policy_last_updatedLatest

Policy last updated 2022-10-05 (Policy states saturation biopsy is not covered / not medically necessary for diagnosis, staging, and management of prostate cancer).

2022-10-05